Acumen Pharmaceuticals, Inc.
ABOS
$1.98
$0.052.59%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 63.99% | 120.01% | 131.50% | 121.65% | 82.35% |
| Gross Profit | -63.99% | -120.01% | -131.50% | -121.65% | -82.35% |
| SG&A Expenses | -5.31% | -2.23% | 1.39% | 7.43% | 19.00% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 48.78% | 87.77% | 92.49% | 86.49% | 63.28% |
| Operating Income | -48.78% | -87.77% | -92.49% | -86.49% | -63.28% |
| Income Before Tax | -63.28% | -110.69% | -107.83% | -95.39% | -67.57% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -63.28% | -110.69% | -107.83% | -95.39% | -67.57% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -63.28% | -110.69% | -107.83% | -95.39% | -67.57% |
| EBIT | -48.78% | -87.77% | -92.49% | -86.49% | -63.28% |
| EBITDA | -48.83% | -87.85% | -92.58% | -86.57% | -63.31% |
| EPS Basic | -61.05% | -103.41% | -83.07% | -57.53% | -23.25% |
| Normalized Basic EPS | -61.08% | -103.45% | -83.09% | -57.51% | -21.69% |
| EPS Diluted | -61.05% | -103.41% | -83.07% | -57.53% | -22.75% |
| Normalized Diluted EPS | -61.08% | -103.45% | -83.09% | -57.51% | -21.69% |
| Average Basic Shares Outstanding | 1.58% | 3.93% | 12.99% | 23.55% | 34.29% |
| Average Diluted Shares Outstanding | 1.58% | 3.93% | 12.99% | 23.55% | 34.29% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |